Contraception in Canada: a Review of Method Choices, Characteristics, Adherence and Approaches to Counselling

Overview

Journal CMAJ

Date 2007 Mar 29

PMID 17389445

Citations 7

Authors

William A Fisher

Amanda Black

Affiliations

Soon will be listed here.

Abstract

Contraception is a significant concern for Canadian women of child-bearing age, their partners and their health care providers. In this narrative review we provide information on current trends and recent changes in Canadians' choices of contraceptive methods. We review the characteristics of contraceptive methods available in Canada, with an emphasis on hormonal methods and newer options such as the transdermal contraceptive patch, the vaginal contraceptive ring and the levonorgestrel-releasing intrauterine system. We also discuss adherence to contraception as well as approaches to counselling to promote adherence and to reduce the risk of sexually transmitted infections in the context of contraception.

Citing Articles

Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.

Philbin M, Parish C, Kinnard E, Reed S, Kerrigan D, Alcaide M J Acquir Immune Defic Syndr. 2020; 84(3):263-270.

PMID: 32530905 PMC: 7483266. DOI: 10.1097/QAI.0000000000002337.

Becoming a 'pharmaceutical person': Medication use trajectories from age 26 to 38 in a representative birth cohort from Dunedin, New Zealand.

Ballantyne P, Norris P, Parachuru V, Thomson W SSM Popul Health. 2018; 4:37-44.

PMID: 29349271 PMC: 5769117. DOI: 10.1016/j.ssmph.2017.11.002.

Characteristics and contributory factors for injectable contraceptive usage among women in Kumasi, Ghana.

Laryea D, Ankobeah F, Morhe E, Amoako Y, Spangenberg K Contracept Reprod Med. 2017; 1:8.

PMID: 29201397 PMC: 5693482. DOI: 10.1186/s40834-016-0019-0.

Barriers and facilitators to family planning access in Canada.

Hulme J, Dunn S, Guilbert E, Soon J, Norman W Healthc Policy. 2015; 10(3):48-63.

PMID: 25947033 PMC: 4748342.

The impact of hormonal contraception on disease-related cyclical symptoms in women with inflammatory bowel diseases.

Gawron L, Goldberger A, Gawron A, Hammond C, Keefer L Inflamm Bowel Dis. 2014; 20(10):1729-33.

PMID: 25105949 PMC: 8449542. DOI: 10.1097/MIB.0000000000000134.

References

Lidegaard O, Edstrom B, Kreiner S . Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002; 65(3):187-96. DOI: 10.1016/s0010-7824(01)00307-9. View

Stewart F, Kaunitz A, LaGuardia K, Karvois D, Fisher A, Friedman A . Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol. 2005; 105(6):1389-96. DOI: 10.1097/01.AOG.0000160430.61799.f6. View

Fisher J, Fisher W, Cornman D, Amico R, Bryan A, Friedland G . Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J Acquir Immune Defic Syndr. 2005; 41(1):44-52. DOI: 10.1097/01.qai.0000192000.15777.5c. View

Andersson K, Odlind V, RYBO G . Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994; 49(1):56-72. DOI: 10.1016/0010-7824(94)90109-0. View

Miller L, Verhoeven C, Hout J . Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol. 2005; 106(3):473-82. DOI: 10.1097/01.AOG.0000175144.08035.74. View

Lee N, Rubin G, Ory H, Burkman R . Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol. 1983; 62(1):1-6. View

Farley T, Rosenberg M, Rowe P, Chen J, Meirik O . Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992; 339(8796):785-8. DOI: 10.1016/0140-6736(92)91904-m. View

Hubacher D, Taylor D . Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001; 345(8):561-7. DOI: 10.1056/NEJMoa010438. View

Sibai B, Odlind V, Meador M, Shangold G, Fisher A, Creasy G . A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril. 2002; 77(2 Suppl 2):S19-26. DOI: 10.1016/s0015-0282(01)03264-2. View

10.

Clark M, Sowers M, Nichols S, Levy B . Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004; 82(6):1580-6. DOI: 10.1016/j.fertnstert.2004.04.064. View

11.

Ostrow D, Fox K, Chmiel J, Silvestre A, Visscher B, Vanable P . Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS. 2002; 16(5):775-80. DOI: 10.1097/00002030-200203290-00013. View

12.

Westhoff C, Morroni C, Kerns J, Murphy P . Bleeding patterns after immediate vs. conventional oral contraceptive initiation: a randomized, controlled trial. Fertil Steril. 2003; 79(2):322-9. DOI: 10.1016/s0015-0282(02)04680-0. View

13.

Vandenbroucke J, Rosing J, Bloemenkamp K, Middeldorp S, Helmerhorst F, Bouma B . Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001; 344(20):1527-35. DOI: 10.1056/NEJM200105173442007. View

14.

von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G . Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet. 2002; 360(9348):1803-10. DOI: 10.1016/S0140-6736(02)11767-3. View

15.

Etchepareborda J, KESSERU E . Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD. Contraception. 1987; 36(2):217-26. DOI: 10.1016/0010-7824(87)90017-5. View

16.

Marchbanks P, McDonald J, Wilson H, Folger S, Mandel M, Daling J . Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002; 346(26):2025-32. DOI: 10.1056/NEJMoa013202. View

17.

Fisher W, Boroditsky R, Morris B . The 2002 Canadian Contraception Study: part 1. J Obstet Gynaecol Can. 2004; 26(6):580-90. DOI: 10.1016/s1701-2163(16)30377-2. View

18.

Westhoff C, Kerns J, Morroni C, Cushman L, Tiezzi L, Murphy P . Quick start: novel oral contraceptive initiation method. Contraception. 2002; 66(3):141-5. DOI: 10.1016/s0010-7824(02)00351-7. View

19.

Ellertson C, Evans M, Ferden S, Leadbetter C, Spears A, Johnstone K . Extending the time limit for starting the Yuzpe regimen of emergency contraception to 120 hours. Obstet Gynecol. 2003; 101(6):1168-71. DOI: 10.1016/s0029-7844(03)00352-1. View

20.

Scholes D, LaCroix A, Ichikawa L, Barlow W, Ott S . Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005; 159(2):139-44. DOI: 10.1001/archpedi.159.2.139. View